News from Visiopharm


New APP: PD-L1 Melanoma

Programmed death-ligand 1 (PD-L1) is a transmembrane protein that binds to the inhibitory receptor programmed death 1 receptor (PD-1), causing a down regulation of immune responses. Tumor cells can upregulate PD-L1 expression and avoid being attacked by the body’s immune system, making an interruption of the PD-1/PD-L1 interaction an attractive method for assisting the immune system in destroying tumor cells.

For more information visit our APP Center

New APP: PD-L1 Lung Cancer

PD-L1 is typically expressed on normal cells but has been observed in immune cells and tumor cells while PD-1 is typically expressed on cytotoxic T-cells and other immune cells. Tumor cells can upregulate PD-L1 expression and avoid being attacked by the body’s immune system, making an interruption of the PD-1/PD-L1 interaction an attractive method for assisting the immune system in destroying tumor cells.

For more information visit our APP Center

Meet us at: Association of Pathology Chairs - 2017 Annual Meeting - Jubilee Meeting

July 25-28, 2017

Washington, DC, USA

Meet us here

 

Meet us here: STP 36th Annual Symoposium

June 24-29, 2017

Montréal, Québec, Canada

Meet us here

Sign up to our newsletter

Visiopharm quantitative digital pathology solutions provide pathologists and scientists with a flexible, powerful suite of software to quantify relevant tissue properties in a fast, objective and reproducible way.

Learn more about us

Visit our APP center

The worlds largest and fastest growing

Visit the complete app center

Publications

Visiopharm software is featured in over 900 international scientific publications. They are based on collaborations with leading scientists in hospitals, biopharmaceutical companies and research institutions around the world. Select a main category to access the publication list.